Gene therapy attack on tough lymphoma shows early promise
NCT ID NCT07211048
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 30 times
Summary
This study is for people with a type of blood cancer called B-cell lymphoma that has returned or not improved with standard treatments. Researchers are testing a new gene therapy (LCAR02) that targets a protein called CD19 on cancer cells. Up to 18 adults will receive the treatment to see if it is safe and can shrink or eliminate the cancer. The goal is to find the right dose and measure any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, 230001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.